Gland Pharma shares rise 2.05% in morning trade

Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer

Shares of Gland Pharma gained 2.05% to trade at Rs 2,059.60 in Monday's session. The stock is trading higher compared to its previous close.

The company's financial performance reveals key insights. The consolidated revenue for the quarter-ending March 2025 stood at Rs 1,424.91 Crore, while the net profit was Rs 186.54 Crore, and the earnings per share (EPS) was Rs 11.32.

Here's a summary of Gland Pharma's key financial data:

In terms of annual consolidated financials, the revenue for the year-ending March 2025 was Rs 5,616.50 Crore, compared to Rs 5,664.72 Crore in the previous year. The net profit stood at Rs 698.53 Crore, a decrease compared to Rs 772.46 Crore in the previous year. The EPS was Rs 42.40, and the book value per share (BVPS) was Rs 555.40. The debt-to-equity ratio was 0.03.

Here is a table summarizing the key annual financial data:

The standalone annual income statement shows sales of Rs 4,116 Crore for the year-ending March 2025. The other income was Rs 215 Crore, leading to a total income of Rs 4,331 Crore. The total expenditure was Rs 2,842 Crore, and the earnings before interest and tax (EBIT) was Rs 1,488 Crore. The interest paid was Rs 22 Crore and tax was Rs 375 Crore. The net profit was Rs 1,089 Crore.

The standalone quarterly income statement for March 2025 shows sales of Rs 1,030 Crore. Other income was Rs 43 Crore, bringing the total income to Rs 1,074 Crore. Total expenditure amounted to Rs 679 Crore, resulting in an EBIT of Rs 394 Crore. After accounting for interest of Rs 3 Crore and tax of Rs 101 Crore, the net profit was Rs 290 Crore.

The cash flow statement for the year-ending March 2025 shows that cash flow from operating activities was Rs 1,073 Crore. Cash flow from investing activities was Rs 1,578 Crore and cash flow from financing activities was Rs -339 Crore. The net cash flow was Rs 2,316 Crore.

The balance sheet for the year-ending March 2025 shows a share capital of Rs 16 Crore and reserves & surplus of Rs 9,738 Crore. Current liabilities are Rs 523 Crore, and other liabilities are Rs 142 Crore, bringing the total liabilities to Rs 10,421 Crore. On the assets side, fixed assets are valued at Rs 1,784 Crore, current assets at Rs 5,766 Crore, and other assets at Rs 2,870 Crore, with total assets also at Rs 10,421 Crore.

Key financial ratios for March 2025 include a basic EPS of Rs 66.15, diluted EPS of Rs 66.15 and a book value per share of Rs 592.08. The dividend per share is Rs 18.00 and face value is 1. The gross profit margin is 40.27%, operating margin is 36.16%, and net profit margin is 26.47%. The return on net worth/equity is 11.17%, ROCE is 15.03%, and return on assets is 10.45%. The current ratio is 11.01, and the quick ratio is 8.62. The debt to equity ratio is 0.00, and the interest coverage ratio is 72.59. The asset turnover ratio is 0.41%, and the inventory turnover ratio is 1.26. The 3 Yr CAGR Sales is -3.29%, and 3 Yr CAGR Net Profit is -5.18%. The valuation ratios include a P/E ratio of 24.07, P/B ratio of 2.69, EV/EBITDA of 14.36 and P/S of 6.37.

Gland Pharma Ltd has announced an earnings call on August 5, 2025, to discuss the standalone and consolidated financial results for the quarter ended June 30, 2025. The meeting of the Board of Directors is scheduled on August 5, 2025, to consider and approve these results. Additionally, Gland Pharma received a GMP Compliance Certificate from the Danish Medicines Agency for aseptically prepared Powder for injection, infusion and inhalation.

Moneycontrol analysis indicates a very bullish sentiment on the stock.

With Gland Pharma trading at Rs 2,059.60, the stock has demonstrated positive movement in today's trading session, reflecting a favorable market position.